公开(公告)号：CA2233550A1

公开(公告)日：1997-04-10

申请号：CA2233550

申请日：1996-09-25

Applicant: ABBOTT LAB

Inventor： BROOKS CLINT D W ,  GUNN DAVID E ,  STEWART ANDREW O ,  CRAIG RICHARD A ,  KOLASA THEODOZYJ ,  BHATIA PRAMILA

IPC: C07D239/26 ,  A61K31/4184 ,  A61K31/421 ,  A61K31/4402 ,  A61K31/454 ,  A61K31/47 ,  A61K31/498 ,  A61K31/506 ,  A61P37/08 ,  A61P43/00 ,  C07D213/30 ,  C07D215/14 ,  C07D215/18 ,  C07D235/12 ,  C07D241/42 ,  C07D263/56 ,  C07D277/24 ,  C07D277/64 ,  C07D417/14 ,  C07D401/14 ,  C07D413/14 ,  C07D235/20 ,  C07D277/30 ,  A61K31/41 ,  A61K31/44 ,  A61K31/495 ,  C07D213/55

Abstract: Compounds having formula (I), wherein W is the same at each occurrence and is selected from optionally substituted quinolyl, optionally substituted benzothiazolyl, optionally substituted benzoxazolyl, optionally substituted benzimidazolyl, optionally substituted quinoxalyl, optionally substituted pyridyl, optionally substituted pyrimidyl, and optionally substituted thiazolyl; R1 and R2 are independently selected from hydrogen, alkyl, haloalkyl, alkoxy, halogen; R3 is a valence bond or is selected from hydrogen and alkyl; X is a valence bond or is selected from alkylene, alkenylen, and alkynylene; and Z is selected from (a) COM, (b) CH=N-O-A-COM, (c) CH2-O-N=A-COM wherein A is selected from alkylene and cycloalkylene, and M is selected from (a) a pharmaceutically acceptable metabolically cleavable group, (b) OR6, (c) -NR7R8, (d) -NR6SO2R9, (e) -NH-Tetrazolyl, and (f) glycinyl inhibit leukotriene biosynthesis and are useful in the treatment of allergic and inflammatory disease states. Also disclosed are leukotriene biosynthesis inhibiting compositions and a method of inhibiting leukotriene biosynthesis.

公开(公告)号：ES2221234T3

公开(公告)日：2004-12-16

申请号：ES98964167

申请日：1998-12-18

Applicant: ABBOTT LAB

Inventor： HOLLADAY MARK W ,  ABREO MELWYN A ,  GUNN DAVID E ,  LIN NAN-HORNG ,  GARVEY DAVID S ,  RYTHER KEITH

IPC: A61K31/427 ,  A61K31/4427 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506 ,  A61P25/00 ,  A61P25/22 ,  A61P25/28 ,  A61P25/30 ,  A61P43/00 ,  C07D401/12 ,  C07D403/12 ,  C07D417/12 ,  C07D455/02 ,  C07D487/04 ,  A61K31/40 ,  A61K31/425 ,  A61K31/44 ,  A61K31/47 ,  A61K31/50 ,  A61K31/505

Abstract: Compuesto teniendo la fórmula (I): **(Fórmula)** o una sal o profármaco del mismo farmacéuticamente admisible, en donde B es **(Fórmula)** en donde R3 es H o alquilo C1-C6; X se selecciona del grupo que se compone de oxígeno y azufre; y E es **(Fórmula)** en donde y es un número entero seleccionado de entre 2 y 3, con los requisitos de que (a) cuando y = 2, R4 se selecciona del grupo que tiene sustituyentes en las posiciones 2, 4-, 2, 5-, 2, 6-, 4, 5-, 4, 6- y 5, 6-del anillo piridina, en donde un sustituyente en la posición 2 es seleccionado del grupo que se compone de (i) -Br, (ii) -Cl, (iii) -F, (iv) -OH, (v) -NH2, (vi) -alquilo C1-C4, y (vii) -alcoxi C1-C3.

公开(公告)号：CA2136075C

公开(公告)日：2004-12-14

申请号：CA2136075

申请日：1993-10-08

Applicant: ABBOTT LAB

Inventor： ABREO MELWYN A ,  GUNN DAVID E ,  LIN NAN-HORNG ,  ELLIOTT RICHARD L ,  GARVEY DAVID S ,  LEBOLD SUZANNE A ,  WASICAK JAMES T

IPC: A61K31/427 ,  A61K31/439 ,  A61K31/44 ,  A61K31/4427 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/497 ,  A61K31/501 ,  A61P25/00 ,  A61P25/28 ,  C07D401/12 ,  C07D403/12 ,  C07D411/12 ,  C07D417/12 ,  C07D471/08 ,  C07D487/04 ,  C07D453/02 ,  A61K31/425 ,  A61K31/435 ,  A61K31/495

Abstract: Novel heterocyclic ether compounds of formula (I), wherein A, B and R2 are specifically defined, or pharmaceutically- acceptable salts or prodrugs thereof, which are selective and potent ligands at cholinergic channel receptors, useful in the treatment of cognitive, neurological and mental disorders characterized by decreased cholinergic function.

公开(公告)号：DK1047690T3

公开(公告)日：2004-07-05

申请号：DK98964167

申请日：1998-12-18

Applicant: ABBOTT LAB

Inventor： HOLLADAY MARK W ,  ABREO MELWYN A ,  GUNN DAVID E ,  LIN NAN-HORNG ,  GARVEY DAVID S ,  RYTHER KEITH ,  LEBOLD SUZANNE A ,  ELLIOTT RICHARD L ,  HE YUN ,  WASIAK JAMES T ,  BAI HAO ,  DART MICHAEL J ,  EHRLICH PAUL P ,  LI YIHONG ,  KINCAID JOHN F ,  SCHKERYANTZ JEFFREY M ,  LYNCH JOHN K

IPC: A61K31/427 ,  A61K31/4427 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506 ,  A61P25/00 ,  A61P25/22 ,  A61P25/28 ,  A61P25/30 ,  A61P43/00 ,  C07D401/12 ,  C07D403/12 ,  C07D417/12 ,  C07D455/02 ,  C07D487/04 ,  A61K31/40 ,  A61K31/425 ,  A61K31/44 ,  A61K31/47 ,  A61K31/50 ,  A61K31/505

公开(公告)号：DE69625080T2

公开(公告)日：2003-10-09

申请号：DE69625080

申请日：1996-09-25

Applicant: ABBOTT LAB

Inventor： BROOKS CLINT D W ,  BHATIA PRAMILA ,  KOLASA THEODOZYJ ,  STEWART ANDREW O ,  GUNN DAVID E ,  CRAIG RICHARD A

IPC: C07D239/26 ,  A61K31/4184 ,  A61K31/421 ,  A61K31/4402 ,  A61K31/454 ,  A61K31/47 ,  A61K31/498 ,  A61K31/506 ,  A61P37/08 ,  A61P43/00 ,  C07D213/30 ,  C07D215/14 ,  C07D215/18 ,  C07D235/12 ,  C07D241/42 ,  C07D263/56 ,  C07D277/24 ,  C07D277/64 ,  C07D417/14 ,  A61K31/395

Abstract: Compounds having the formula: wherein W is the same at each occurrence and is selected from optionally substituted quinolyl, optionally substituted benzothiazolyl, optionally substituted benzoxazolyl, optionally substituted benzimidazolyl, optionally substituted quinoxalyl, optionally substituted pyridyl, optionally substituted pyrimidyl, and optionally substituted thiazolyl; R1 and R2 are independently selected from hydrogen, alkyl, halolalkyl, alkoxy, halogen; R3 is a valence bond or is selected from hydrogen and alkyl; X is a valence bond or is selected from alkylene, alkenylen, and alkynylene; and Z is selected from (a) COM, (b) CH=N-O-A-COM, (c) CH2-O-N=A-COM wherein A is selected from alkylene and cycloalkylene, and M is selected from (a) a pharmaceutically acceptable metabolically cleavable group, (b) -OR6, (c) -NR7R8, (d)-NR6SO2R9, (e)-NH-Tetrazolyl, and (f) glycinyl inhibit leukotriene biosynthesis and are useful in the treatment of allergic and inflammatory disease states. Also disclosed are leukotriene biosynthesis inhibiting compositions and a method of inhibiting leukotriene biosynthesis.

公开(公告)号：AT228504T

公开(公告)日：2002-12-15

申请号：AT96932335

申请日：1996-09-25

Applicant: ABBOTT LAB

Inventor： BROOKS CLINT D W ,  BHATIA PRAMILA ,  KOLASA THEODOZYJ ,  STEWART ANDREW O ,  GUNN DAVID E ,  CRAIG RICHARD A

IPC: C07D239/26 ,  A61K31/4184 ,  A61K31/421 ,  A61K31/4402 ,  A61K31/454 ,  A61K31/47 ,  A61K31/498 ,  A61K31/506 ,  A61P37/08 ,  A61P43/00 ,  C07D213/30 ,  C07D215/14 ,  C07D215/18 ,  C07D235/12 ,  C07D241/42 ,  C07D263/56 ,  C07D277/24 ,  C07D277/64 ,  C07D417/14 ,  A61K31/395

Abstract: Compounds having the formula: wherein W is the same at each occurrence and is selected from optionally substituted quinolyl, optionally substituted benzothiazolyl, optionally substituted benzoxazolyl, optionally substituted benzimidazolyl, optionally substituted quinoxalyl, optionally substituted pyridyl, optionally substituted pyrimidyl, and optionally substituted thiazolyl; R1 and R2 are independently selected from hydrogen, alkyl, halolalkyl, alkoxy, halogen; R3 is a valence bond or is selected from hydrogen and alkyl; X is a valence bond or is selected from alkylene, alkenylen, and alkynylene; and Z is selected from (a) COM, (b) CH=N-O-A-COM, (c) CH2-O-N=A-COM wherein A is selected from alkylene and cycloalkylene, and M is selected from (a) a pharmaceutically acceptable metabolically cleavable group, (b) -OR6, (c) -NR7R8, (d)-NR6SO2R9, (e)-NH-Tetrazolyl, and (f) glycinyl inhibit leukotriene biosynthesis and are useful in the treatment of allergic and inflammatory disease states. Also disclosed are leukotriene biosynthesis inhibiting compositions and a method of inhibiting leukotriene biosynthesis.

公开(公告)号：AU5355794A

公开(公告)日：1994-05-09

申请号：AU5355794

申请日：1993-10-08

Applicant: ABBOTT LAB

Inventor： ABREO MELWYN A ,  GUNN DAVID E ,  LIN NAN-HORNG ,  ELLIOTT RICHARD L ,  GARVEY DAVID S ,  LEBOLD SUZANNE A ,  WASICAK JAMES T

IPC: A61K31/427 ,  A61K31/439 ,  A61K31/44 ,  A61K31/4427 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/497 ,  A61K31/501 ,  A61P25/00 ,  A61P25/28 ,  C07D401/12 ,  C07D403/12 ,  C07D411/12 ,  C07D417/12 ,  C07D471/08 ,  C07D487/04 ,  A61K31/425 ,  A61K31/445 ,  A61K31/495 ,  A61K31/50 ,  A61K31/505

Abstract: Novel heterocyclic ether compounds of formula (I), wherein A, B and R are specifically defined, or pharmaceutically-acceptable salts or prodrugs thereof, which are selective and potent ligands at cholinergic channel receptors, useful in the treatment of cognitive, neurological and mental disorders characterized by decreased cholinergic function.

公开(公告)号：MX9306274A

公开(公告)日：1994-04-29

申请号：MX9306274

申请日：1993-10-08

Applicant: ABBOTT LAB

Inventor： ELLIOTT RICHARD L ,  LEBOLD SUZANNE A ,  WASICAK JAMES T ,  GARVEY DAVID S ,  ABREO MELWYN A ,  GUNN DAVID E ,  LIN NAN-HORNG

IPC: C07D403/12